Dr. Ahmed Farhan
Ask anyone who has started semaglutide or tirzepatide what worries them most, and “muscle loss” usually comes up right after nausea.
Scroll social media and you’ll find posts claiming that up to 40 percent of the weight lost on these drugs is muscle, not fat — often framed as if the medication is quietly eating away at your strength.
That statistic has a real basis in trial data, but stripped of context it paints a scarier picture than the evidence supports.
Two major 2026 medical conferences and a fresh wave of published trials have now looked at this question directly.
The honest answer sits in between the panic and the reassurance: modest, largely preventable muscle loss is real. Still, it is not the dominant story of what happens to your body on these drugs — and who is most at risk is now much clearer than it was a year ago.
Why This Question Is Suddenly Everywhere
The timing isn’t random. At the European Congress on Obesity in Istanbul in May 2026, researchers presented new body-composition data specifically addressing how much of GLP-1-related weight loss is fat versus muscle.
A few weeks later, the American Diabetes Association’s 2026 Scientific Sessions in New Orleans devoted an entire symposium to the topic, with specialists pushing the conversation beyond simple weight-loss numbers and into questions about long-term metabolic function.
Then, in a development that changes the pipeline conversation entirely, a phase 2 trial combining semaglutide with an experimental muscle-preserving antibody called bimagrumab was published in Nature Medicine, showing that the two problems — losing fat and protecting muscle — might not have to trade off against each other much longer.
Regeneron reported interim results from a similar combination trial around the same time. Muscle preservation, in other words, has gone from an afterthought in GLP-1 research to one of the field’s most active areas.
What the Research Actually Shows
The most detailed data on this question comes from the STEP-1 trial, the pivotal study that led to semaglutide’s approval for weight management.
In a dual-energy X-ray absorptiometry (DXA) substudy of that trial — a gold-standard method for measuring body composition — participants taking semaglutide 2.4 mg weekly for 68 weeks lost an average of about 19 percent of their total fat mass and roughly 10 percent of their total lean body mass.
Because fat mass fell by a larger percentage than lean mass, the proportion of the body made up of lean tissue actually increased slightly — a sign that overall body composition improved even as the absolute lean-mass number went down.
A similar pattern showed up in the SUSTAIN-8 substudy, which compared semaglutide directly against canagliflozin (an SGLT-2 inhibitor) in people with type 2 diabetes: both fat mass and lean mass declined with treatment, without a statistically significant difference in lean-mass loss between the two drug classes — evidence that some lean-tissue loss accompanies weight loss generally, not something unique to GLP-1 pharmacology.
Newer data presented at ECO2026 pushed the reassurance further. In that research, most weight lost with GLP-1-based obesity drugs was fat mass — on the order of 80 to 85 percent — with an average skeletal muscle mass reduction of only around 5 percent, and relative muscle mass preserved or increased in more than 70 percent of patients once researchers accounted for how much fat was lost alongside it.
This is emerging, conference-presented evidence rather than a published peer-reviewed paper, so it should be read as a promising, not yet fully settled, data point — but it points in the same direction as the trial substudies.
Preclinical work adds a mechanistic angle. A study published in Cell Reports Medicine found that in obese mice, GLP-1 medicines reduced body fat substantially alongside only a small, statistically modest drop in lean body mass — and that the loss of liver mass actually exceeded the loss of muscle mass.
A small proof-of-concept human trial in the same paper pointed in a similar direction, though because the core findings come from animal models, they should be read as mechanistic support rather than direct evidence of what happens in human muscle.
So How Much Muscle Is Really Lost?
The honest range across trials is that somewhere between roughly a quarter and 40 percent of total weight lost on GLP-1 therapy is lean mass — not exclusively muscle, since DXA-measured “lean mass” also includes water, glycogen, connective tissue, and organs.
The phase 2 BELIEVE trial, published in Nature Medicine in 2026, put a specific number on the semaglutide-alone group: participants lost about 7.4 percent of their lean mass over the treatment period.
Regeneron’s interim COURAGE trial results, reported around the same time, estimated that roughly 35 percent of semaglutide-induced weight loss came from lean tissue in its comparison group.
These numbers are larger than the reassuring ECO2026 relative-preservation figures, and that’s an important, genuine tension in the current evidence — different trials, using different measurement approaches and patient populations, haven’t yet converged on one settled number.
What they agree on is the direction: meaningful fat loss dominates, muscle loss is real but proportionally smaller, and it responds to the interventions covered further down.
Why This Matters Beyond the Mirror
Muscle preservation isn’t just about appearance or gym performance. Speaking at the ADA 2026 symposium, endocrinologist Ian Neeland highlighted that each kilogram of muscle mass lost reduces resting energy expenditure by roughly 13 kilocalories, compared with about 4 kilocalories for a kilogram of fat — meaning muscle loss can make weight regain more likely after treatment stops, by lowering the baseline number of calories the body burns at rest.
Muscle mass is also central to insulin sensitivity: skeletal muscle is where most of the body’s glucose disposal happens after a meal, so preserving it plausibly supports the same blood-sugar benefits that make GLP-1 drugs valuable for diabetes management in the first place, though this specific causal link in humans on GLP-1 therapy is still an active area of study rather than settled fact.
And for older adults in particular, muscle strength is directly tied to fall risk, mobility, and independence — stakes that go well beyond how someone looks after weight loss.
The Drug Pipeline Trying to Solve This
The clearest sign that the field takes this seriously is the emergence of combination therapies designed specifically to decouple fat loss from muscle loss.
In the BELIEVE trial, adding bimagrumab — an antibody that blocks activin type II receptors, a pathway that normally restrains muscle growth — to semaglutide cut lean-mass loss from 7.4 percent (semaglutide alone) to 2.9 percent, while producing greater total weight loss than semaglutide alone.
In the highest-dose combination group, roughly 92 percent of the weight lost was fat mass. Regeneron’s competing COURAGE trial is testing a similar approach with a different antibody, trevogrumab, with interim data showing that combination approaches spared an estimated 50 to 80 percent of the lean mass that would otherwise be lost with semaglutide alone.
It’s worth being clear about where these findings stand: bimagrumab is not an approved drug, this was a 48-to-72-week phase 2 trial, and bimagrumab groups saw more treatment discontinuations due to side effects like muscle spasms than the semaglutide or placebo groups.
Whether these approaches reach the market, and what long-term safety looks like, remains genuinely unresolved — but they represent the most direct evidence yet that muscle loss on GLP-1 drugs is a solvable pharmacological problem, not an unavoidable cost of the mechanism.
Common Misconceptions
“GLP-1 drugs specifically target muscle tissue.”
They don’t. GLP-1 receptor agonists work primarily on appetite and gastric emptying; the lean-mass changes seen in trials are a byproduct of rapid, substantial calorie deficit and weight loss — the same phenomenon seen with any aggressive diet, bariatric surgery, or other weight-loss method. The SUSTAIN-8 comparison against canagliflozin, a drug with an entirely different mechanism, showing similar lean-mass changes, supports this.
“Lean mass loss and muscle loss are the same thing.”
DXA-measured “lean mass” includes water, glycogen stores, connective tissue, and organs, not just skeletal muscle. Some of the early, rapid “lean mass” drop seen in the first weeks of GLP-1 treatment reflects fluid shifts rather than true muscle protein loss, which is part of why headline percentages can overstate the muscle-specific effect.
“If I’m losing lean mass, the drug isn’t working the way it should.”
Some lean-tissue loss accompanies essentially all significant weight loss, regardless of method. The more useful clinical question isn’t whether any lean mass is lost, but whether the proportion lost is disproportionate to the fat lost, and whether strength and function are preserved — both of which are modifiable through nutrition and exercise, discussed below.
What We Know — and What We Don’t
Established
Across multiple randomized trials, GLP-1-based weight loss reduces both fat mass and lean mass, with fat mass loss consistently larger in absolute and percentage terms. Adequate protein intake and resistance training are established, evidence-based interventions for preserving lean mass during any significant weight loss, GLP-1-related or not.
Emerging
Conference-presented data (ECO2026) suggesting relative muscle mass is preserved or increased in a majority of patients is promising but not yet published in full peer-reviewed form. Antibody-based combination therapies (bimagrumab, trevogrumab) show strong phase 2 signals for muscle preservation but are unapproved and unproven at scale.
Unresolved
Researchers don’t yet have a large, converged estimate of exactly what fraction of GLP-1-related weight loss is true skeletal muscle versus other lean tissue, or how outcomes differ by age, baseline muscle mass, dose, and rate of weight loss.
Long-term functional outcomes — strength, falls, independence — beyond the 1-to-2-year window of most current trials remain an open question, as do the durability and safety of muscle-preserving combination drugs.
Who Should Pay Closer Attention
The muscle-loss conversation matters more for some people than others. Those at higher risk of clinically meaningful loss include:
- Older adults, who typically start with less muscle mass and have a harder time rebuilding it (age-related muscle loss, or sarcopenia, is already a risk factor before any medication is added)
- Anyone losing weight very rapidly, particularly with fast dose escalation rather than a gradual titration schedule
- People with low protein intake, often a downstream effect of the appetite suppression these drugs cause
- Those who are sedentary or unable to do resistance exercise due to joint pain, mobility limits, or other health conditions
- People losing a large percentage of body weight overall (generally above 15 to 20 percent), where the absolute amount of muscle lost can become substantial even if the proportion lost is unremarkable
For these groups, a conversation with a physician or registered dietitian about baseline strength assessment and a structured nutrition and exercise plan is particularly worthwhile before or early in treatment, rather than after strength or function has noticeably declined.
Practical, Evidence-Based Steps to Protect Muscle
The interventions with the strongest evidence behind them are unglamorous and consistent across obesity-medicine guidance: protein and resistance training.
Protein
Joint clinical guidance from the Obesity Society and allied nutrition and lifestyle-medicine organizations recommends a target of roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day during active GLP-1-assisted weight loss, spread across meals rather than concentrated in one sitting.
Because appetite suppression can make hitting that target harder, prioritizing protein-dense foods early in each meal, and using protein-forward snacks or supplements when whole-food intake falls short, is a reasonable and evidence-supported strategy — not a sign that something has gone wrong.
Resistance training
Structured resistance exercise, at least two to three sessions per week targeting major muscle groups, is the single most effective non-pharmacological intervention for preserving muscle during weight loss, GLP-1-assisted or otherwise.
It doesn’t need to be elaborate: bodyweight or resistance-band training, performed consistently, provides a meaningful stimulus, particularly for people newer to exercise or managing joint issues.
Pacing and monitoring
A more gradual dose titration, guided by a clinician, tends to produce a steadier rate of weight loss, which several obesity-medicine sources note may give muscle-preservation habits more time to work compared with aggressive dose escalation.
For people with risk factors above, discussing a baseline and follow-up body-composition or strength assessment with a healthcare provider can help distinguish expected, modest lean-mass change from a pattern worth addressing directly.
FAQ
Does everyone on GLP-1 drugs lose muscle?
Essentially everyone who loses a significant amount of weight loses some lean tissue, GLP-1 drugs included — but the amount varies widely and is influenced heavily by protein intake, exercise, age, and rate of weight loss. It is not an inevitable, fixed side effect experienced identically by everyone.
Is the muscle loss permanent?
Not inherently. Muscle responds to training and adequate protein at any age, including during and after GLP-1 treatment. The clearest current evidence gap is long-term functional outcomes beyond the one-to-two-year window most trials have studied so far.
Do I need a protein supplement?
Not necessarily — whole-food sources can meet the recommended protein range for many people. Supplements (protein shakes, bars) are a practical tool for people whose appetite suppression makes hitting protein targets through food alone difficult, not a requirement for everyone.
Will resistance training even work while I’m in a calorie deficit this large?
Yes. Resistance training’s benefit during weight loss is preserving existing muscle and function, not necessarily building large amounts of new muscle — and that preservation effect is well-supported even during significant calorie deficits.
Should I ask my doctor for a body-composition scan?
It’s a reasonable question to raise, particularly for older adults or anyone losing weight rapidly, though DXA scans aren’t universally available or necessary for every patient. A clinician can help decide whether it adds useful information for your specific situation.
The Bottom Line
The internet’s fear-headline version of this story — that GLP-1 drugs are quietly hollowing out your muscle — overstates the evidence.
The more accurate picture, drawn from trial substudies, 2026 conference data, and now a wave of pharmaceutical research specifically targeting this problem, is that fat loss dominates, muscle loss is real but proportionally modest for most people, and it responds meaningfully to protein intake and resistance training — the same two levers that protect muscle during any significant weight loss.
The people who should pay closest attention are older adults, those losing weight very rapidly, and anyone unable to maintain adequate protein or physical activity during treatment.
For everyone else, the research increasingly supports treating muscle preservation as a manageable part of the plan, not a reason to avoid an otherwise effective treatment — and a new generation of combination therapies suggests this trade-off may shrink further in the next few years.
As always, decisions about starting, adjusting, or combining any of these therapies belong in a conversation with your own healthcare provider, who can weigh your individual risk factors and history.
References
- Wilding, J.P.H., et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. 10.1210/jendso/bvab048.030
- STEP 1 Trial primary results — New England Journal of Medicine (DXA substudy analyses).
- SUSTAIN 8 substudy: Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes — Diabetologia / PMC. doi: 10.1007/s00125-019-05065-8
- “Muscle mass is preserved after obesity drug treatment, study suggests” — research presented at the European Congress on Obesity (ECO2026), Istanbul, May 2026, via Medical Xpress.
- Langer, A., et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans — Cell Reports Medicine, 2026. DOI: 10.1016/j.xcrm.2026.102665
- Heymsfield, S.B., Aronne, L.J., Montgomery, P., et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE) — Nature Medicine, 2026.
- Regeneron Pharmaceuticals. Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide-Induced Weight Loss by Preserving Lean Mass — company press release, 2026.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies — peer-reviewed narrative review, 2026.
- Preserving Lean Mass in Weight Loss Management — joint clinical guidance (American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, The Obesity Society).
- Neeland, I. Preserving lean body mass index while on GLP-1-based therapies — presented at American Diabetes Association 2026 Scientific Sessions, New Orleans, June 2026, via AJMC.
- Optimizing GLP-1 therapies for obesity and diabetes management — peer-reviewed review, PMC, 2026.
